| Name | Title | Contact Details |
|---|---|---|
Robb Vaules |
Senior Vice President, Marketing and Western US Sales | Profile |
Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research. We are headquartered in Cambridge UK. Our eight additional sales, production, and distribution offices are located in Asia, UK, and the USA. Our mission is to help scientists to discover more. Our vision is to be the brand most recommended by life science researchers. We recognise the importance of providing clear and timely information to our existing and potential shareholders and hope that you will find this website helpful on informing your investment decisions.
Prodenco Group Inc is a Sioux City, IA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Labelcity, Inc. is a Jim Thorpe, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Corgenix Medical Corporation is a Broomfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.